Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-09-30
2010-11-02
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S139100, C424S141100, C424S142100, C424S143100
Reexamination Certificate
active
07824675
ABSTRACT:
The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4444887 (1984-04-01), Hoffmann
patent: 4474893 (1984-10-01), Reading
patent: 4714681 (1987-12-01), Reading
patent: 4716111 (1987-12-01), Osband et al.
patent: 4925648 (1990-05-01), Hansen et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4946788 (1990-08-01), DeLespesse
patent: 5112946 (1992-05-01), Maione
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5258498 (1993-11-01), Huston et al.
patent: 5310662 (1994-05-01), Evans et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5349052 (1994-09-01), Delgado et al.
patent: 5349053 (1994-09-01), Landolfi
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5359039 (1994-10-01), Smith et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5413923 (1995-05-01), Kucherlapati et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5447851 (1995-09-01), Buetler et al.
patent: 5464938 (1995-11-01), Smith et al.
patent: 5474981 (1995-12-01), Leder et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5573920 (1996-11-01), Randle
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5612460 (1997-03-01), Zalipsky
patent: 5622929 (1997-04-01), Willner et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5811097 (1998-09-01), Allison et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6303336 (2001-10-01), Spear et al.
patent: 2045869 (1991-12-01), None
patent: 2260754 (1998-01-01), None
patent: 0 239 400 (1987-09-01), None
patent: 0 282 317 (1988-09-01), None
patent: 0 307 434 (1989-03-01), None
patent: 0 367 166 (1990-05-01), None
patent: 0 393 438 (1990-10-01), None
patent: 0 396 387 (1990-11-01), None
patent: 0 399 816 (1990-11-01), None
patent: 0 401 384 (1990-12-01), None
patent: 0 506 477 (1992-09-01), None
patent: 0 519 596 (1992-12-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 585 939 (1994-03-01), None
patent: 0 592 106 (1994-04-01), None
patent: 0 682 110 (1995-11-01), None
patent: 0 822 984 (1998-02-01), None
patent: WO-89/01036 (1989-02-01), None
patent: WO-89/12624 (1989-12-01), None
patent: WO-90/13649 (1990-11-01), None
patent: WO-91/00360 (1991-01-01), None
patent: WO-91/02078 (1991-02-01), None
patent: WO-91/06570 (1991-05-01), None
patent: WO-91/09045 (1991-06-01), None
patent: WO-91/09967 (1991-07-01), None
patent: WO-91/10741 (1991-07-01), None
patent: WO-91/14438 (1991-10-01), None
patent: WO-92/05793 (1992-04-01), None
patent: WO-92/06194 (1992-04-01), None
patent: WO-92/08495 (1992-05-01), None
patent: WO-92/08802 (1992-05-01), None
patent: WO-92/22324 (1992-12-01), None
patent: WO-93/11236 (1993-06-01), None
patent: WO-93/17715 (1993-09-01), None
patent: WO-93/20219 (1993-10-01), None
patent: WO-93/21232 (1993-10-01), None
patent: WO-94/09137 (1994-04-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-95/06058 (1995-03-01), None
patent: WO-95/15982 (1995-06-01), None
patent: WO-95/20401 (1995-08-01), None
patent: WO-96/04388 (1996-02-01), None
patent: WO-96/14328 (1996-05-01), None
patent: WO-96/26736 (1996-09-01), None
patent: WO-96/33735 (1996-10-01), None
patent: WO-96/34095 (1996-10-01), None
patent: WO-96/34096 (1996-10-01), None
patent: WO-96/39515 (1996-12-01), None
patent: WO-96/40281 (1996-12-01), None
patent: WO-97/04658 (1997-02-01), None
patent: WO-97/06251 (1997-02-01), None
patent: WO-97/33904 (1997-09-01), None
patent: WO-97/34911 (1997-09-01), None
patent: WO-98/02543 (1998-01-01), None
patent: WO-98/06842 (1998-02-01), None
patent: WO-98/07832 (1998-02-01), None
patent: WO-98/07880 (1998-02-01), None
patent: WO-98/16654 (1998-04-01), None
patent: WO-98/18921 (1998-05-01), None
patent: WO-98/24893 (1998-06-01), None
patent: WO-98/25967 (1998-06-01), None
patent: WO-98/30693 (1998-07-01), None
patent: WO-98/30694 (1998-07-01), None
patent: WO-98/31799 (1998-07-01), None
patent: WO-98/32466 (1998-07-01), None
patent: WO-98/32856 (1998-07-01), None
patent: WO-98/41629 (1998-09-01), None
patent: WO-98/46645 (1998-10-01), None
patent: WO-98/50433 (1998-11-01), None
patent: WO-98/51346 (1998-11-01), None
patent: WO-98/54202 (1998-12-01), None
patent: WO-98/56892 (1998-12-01), None
US 5,843,791, 12/1998, Hauptmann et al. (withdrawn)
Zhang (2004, Curr. Opin. Struct. Biol. 14:154-160).
Toussirot et al. (2004, Expert Opin. Pharmacother. 5:581-594).
Jacobsohn (2002, Expert Opin. Investig. Drugs 11:1271-1280).
Hoentjen et al. (2009, World J. Gastroenterol. 152067-2073).
Ramos-Casals et al. (2008, Best Practice & Research Clinical Rheumatology 22:847-861).
Pirard et al. (2006, Dermatology 213:182-186).
Winkelmann et al. (2008, J. Neurol. 255 [Suppl. 6]:109-114).
Sicotte et al. (2001, Neurology 57:1885-1888).
U.S. Appl. No. 08/509,024, Not Published, Spear, et al.
Adams, et al., “Complementary DNA sequencing: expressed sequence tags and human genome project,”Science, 252:1651-1656 (1991).
Adams, et al., “Sequence identification of 2,375 human brain genes,”Nature, 355:632-634 (1992).
Aggarwal, et al., “Tumor necrosis factors: developments during the last decade,”Eur. Cytokine Netw., 7(2):93-124 (May 1996).
Altschul, et al., “Basic local alignment search tool,”J. Mol. Biol., 215:403-410 (Oct. 1990).
Ames, et al., “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,”J. Immunol. Meth., 184:177-186 (Aug. 1995).
Armitage, R.J., “Tumor necrosis factor receptor superfamily members and their ligands,”Curr. Opin. Immunol., 6:407-413 (Jun. 1994).
Ashkenazi, et al., “Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin,”Proc. Natl. Acad. Sci. USA, 88:10535-10539 (1991).
Badley, et al., “Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes,”J. Virol., 70:199-206 (Jan. 1996).
Baens, et al., “Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid,”Genomics, 16:214-218 (1993).
Baker, et al., “Chromosomal location of the human tumor necrosis factor receptor genes,”Cytogenet. Cell Genet., 57:117-118 (1991).
Banchereau, et al., “Long-term hu
Gentz Reiner L.
Ni Jian
Rosen Craig A.
Human Genome Sciences Inc.
Kemmerer Elizabeth C.
LandOfFree
Use of an antibody that binds human tumor necrosis factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of an antibody that binds human tumor necrosis factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an antibody that binds human tumor necrosis factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252050